$IVVD
Invivyd, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022017242 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.20M $14.62M $8.704M
YoY Change 19.44% 105.22% 136.71%
% of Gross Profit
Research & Development $30.13M $37.13M $92.04M
YoY Change -33.58% 5.88% 170.44%
% of Gross Profit
Depreciation & Amortization $0.00 $5.000K $4.000K
YoY Change
% of Gross Profit
Operating Expenses $47.33M $51.75M $100.7M
YoY Change -21.66% 15.79% 160.25%
Operating Profit -$47.33M -$51.75M -$100.7M
YoY Change -21.66% 15.79% 160.25%
Interest Expense $100.0K $100.0K
YoY Change 334.78% 1011.11%
% of Operating Profit
Other Income/Expense, Net $2.244M $759.0K $73.00K
YoY Change 5118.6% 4116.67% 711.11%
Pretax Income -$45.09M -$50.99M -$100.7M
YoY Change -25.32% 14.14% 160.12%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$45.09M -$50.99M -$100.7M
YoY Change -25.32% 14.14% 160.12%
Net Earnings / Revenue
Basic Earnings Per Share -$0.42 -$0.47 -$0.93
Diluted Earnings Per Share -$0.42 -$0.47 -$933.2K
COMMON SHARES
Basic Shares Outstanding 108.8M 108.2M 107.9M
Diluted Shares Outstanding 108.4M 108.2M 107.9M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $418.7M $474.9M $532.2M
YoY Change -37.17% 20.99% 483.27%
Cash & Equivalents $278.2M $474.9M $532.2M
Short-Term Investments $140.5M $0.00 $0.00
Other Short-Term Assets $2.100M $6.476M $22.08M
YoY Change 262.69% 2381.23% 508.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $421.6M $481.4M $554.3M
YoY Change -38.01% 21.54% 484.25%
LONG-TERM ASSETS
Property, Plant & Equipment $1.429M $91.00K $87.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $236.0K $299.0K $237.0K
YoY Change -96.14% -84.53%
Total Long-Term Assets $3.151M $3.251M $1.972M
YoY Change -48.47% 68.18%
TOTAL ASSETS
Total Short-Term Assets $421.6M $481.4M $554.3M
Total Long-Term Assets $3.151M $3.251M $1.972M
Total Assets $424.7M $484.6M $556.3M
YoY Change -38.11% 21.76% 486.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.77M $14.23M $18.68M
YoY Change -4.52% 32.81% 65.08%
Accrued Expenses $28.97M $52.62M $76.54M
YoY Change -18.35% 93.61% 340.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.13M $67.88M $95.53M
YoY Change -13.05% 79.12% 233.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.13M $67.88M $95.53M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $47.30M $69.77M $96.88M
YoY Change -10.84% 84.07% 237.71%
SHAREHOLDERS EQUITY
Retained Earnings -$488.9M -$443.8M -$392.8M
YoY Change 133.81% 198.45%
Common Stock $866.2M $858.6M $852.2M
YoY Change 2.85% 21006.29%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00 $0.00
YoY Change
Treasury Stock Shares $0.00 $992.6K $0.00
Shareholders Equity $377.4M $414.8M $459.4M
YoY Change
Total Liabilities & Shareholders Equity $424.7M $484.6M $556.3M
YoY Change -38.11% 21.76% 486.33%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$45.09M -$50.99M -$100.7M
YoY Change -25.32% 14.14% 160.12%
Depreciation, Depletion And Amortization $0.00 $5.000K $4.000K
YoY Change
Cash From Operating Activities -$56.14M -$57.39M -$59.05M
YoY Change 3.55% 70.96% 148.72%
INVESTING ACTIVITIES
Capital Expenditures $470.0K -$17.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$140.4M $0.00 $49.00M
YoY Change -25.59%
Cash From Investing Activities -$140.8M -$17.00K $49.00M
YoY Change -25.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.000K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K 74.00K 45.00K
YoY Change -99.92% -99.98%
NET CHANGE
Cash From Operating Activities -56.14M -57.39M -59.05M
Cash From Investing Activities -140.8M -17.00K 49.00M
Cash From Financing Activities 250.0K 74.00K 45.00K
Net Change In Cash -196.7M -57.34M -10.00M
YoY Change -329.38% -119.03% -57.86%
FREE CASH FLOW
Cash From Operating Activities -$56.14M -$57.39M -$59.05M
Capital Expenditures $470.0K -$17.00K $0.00
Free Cash Flow -$56.61M -$57.38M -$59.05M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001832038
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
CY2022Q2 adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40703
dei Entity Registrant Name
EntityRegistrantName
Adagio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1403134
dei Entity Address Address Line1
EntityAddressAddressLine1
1601 Trapelo Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 178
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
819-0080
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ADGI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
108830525
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
474885000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
542224000
CY2022Q2 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
49194000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6476000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25293000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
481361000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
616711000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2861000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
299000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3297000
CY2022Q2 us-gaap Assets
Assets
484612000
CY2021Q4 us-gaap Assets
Assets
620091000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
14232000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5783000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52624000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56277000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
969000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
58000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
67883000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62060000
CY2022Q2 adgi Early Exercise Liability
EarlyExerciseLiability
1000
CY2021Q4 adgi Early Exercise Liability
EarlyExerciseLiability
6000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1889000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6000
CY2022Q2 us-gaap Liabilities
Liabilities
69773000
CY2021Q4 us-gaap Liabilities
Liabilities
62072000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109773173
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108780525
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111251660
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
110782909
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
992648
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
468751
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
858593000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
850125000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-443765000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-292109000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
414839000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
558019000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
484612000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
620091000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37129000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35067000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129164000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69204000
CY2021Q2 adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
2500000
adgi Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
3500000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14620000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7124000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23324000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10695000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
51749000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
44691000
us-gaap Operating Expenses
OperatingExpenses
152488000
us-gaap Operating Expenses
OperatingExpenses
83399000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-51749000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44691000
us-gaap Operating Income Loss
OperatingIncomeLoss
-152488000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83399000
CY2022Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
759000
CY2021Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
18000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
832000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
26000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
759000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
832000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44673000
us-gaap Net Income Loss
NetIncomeLoss
-151656000
us-gaap Net Income Loss
NetIncomeLoss
-83373000
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50990000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44673000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-151648000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83373000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-178.86
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-178.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-663.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-663.94
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108166890
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108166890
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
249769
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
249769
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108019051
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108019051
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125574
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125574
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-65249000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
587000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-38700000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-103362000
CY2021Q2 adgi Net Issuance Cost Of Convertible Preferred Stock
NetIssuanceCostOfConvertiblePreferredStock
337000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
66000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3342000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44673000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-144624000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
558019000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1983000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
8000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-100666000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
459392000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6361000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
414839000
us-gaap Profit Loss
ProfitLoss
-151656000
us-gaap Profit Loss
ProfitLoss
-83373000
us-gaap Share Based Compensation
ShareBasedCompensation
8344000
us-gaap Share Based Compensation
ShareBasedCompensation
3929000
adgi Non Cash Payments
NonCashPayments
0
adgi Non Cash Payments
NonCashPayments
66000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-194000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
211000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
us-gaap Depreciation
Depreciation
9000
us-gaap Depreciation
Depreciation
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18825000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1146000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2998000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8449000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2159000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3653000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21054000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
58000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-214000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116441000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57311000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48983000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
335264000
adgi Payments Of Initial Public Offering Costs
PaymentsOfInitialPublicOfferingCosts
0
adgi Payments Of Initial Public Offering Costs
PaymentsOfInitialPublicOfferingCosts
432000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
123000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
334832000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67339000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
277521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
542224000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114988000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
474885000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
392509000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1728000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
adgi Operating Lease Right Of Use Asset Recognized Under Asc842
OperatingLeaseRightOfUseAssetRecognizedUnderAsc842
1344000
adgi Deferred Offering And Issuance Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
0
adgi Deferred Offering And Issuance Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingAndIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
1602000
CY2021Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
five-for-one
us-gaap Net Income Loss
NetIncomeLoss
-151700000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-443800000
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q3 adgi Lessee Operating Lease Total Lease Space
LesseeOperatingLeaseTotalLeaseSpace
9600
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs. Prior to the IPO, significant estimates and assumptions also included the valuation of common stock and resulting stock-based compensation expense. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is monitoring the potential impact of the COVID-19 pandemic on its business and condensed consolidated financial statements. The Company is not aware of any specific event or circumstance that would require any update to its estimates or judgments reflected in these condensed consolidated financial statements or a revision of the carrying value of its assets or liabilities as of the issuance date of these condensed consolidated financial statements. These estimates may change as new events occur and additional information is obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2016Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2016Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1400000
CY2016Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1700000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1728000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
308000
CY2021Q4 us-gaap Other Deferred Compensation Arrangements Liability Current And Noncurrent
OtherDeferredCompensationArrangementsLiabilityCurrentAndNoncurrent
6000
CY2022Q1 us-gaap Other Deferred Compensation Arrangements Liability Current And Noncurrent
OtherDeferredCompensationArrangementsLiabilityCurrentAndNoncurrent
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1426000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q3 us-gaap Sale Leaseback Transaction Monthly Rental Payments
SaleLeasebackTransactionMonthlyRentalPayments
400000
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2021Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2022Q2 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2021Q2 adgi Fair Value Transfers Between Levels Transfers Amount
FairValueTransfersBetweenLevelsTransfersAmount
0
CY2022Q2 adgi Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
4392000
CY2021Q4 adgi Prepaid External Research Development And Manufacturing Expense Current
PrepaidExternalResearchDevelopmentAndManufacturingExpenseCurrent
20582000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
456000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3190000
CY2022Q2 adgi Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1628000
CY2021Q4 adgi Prepaid Compensation And Related Expenses
PrepaidCompensationAndRelatedExpenses
1521000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6476000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25293000
CY2021Q3 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
five-for-one
CY2022Q2 adgi Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
44919000
CY2021Q4 adgi Accrued External Research Development And Manufacturing Expenses Current
AccruedExternalResearchDevelopmentAndManufacturingExpensesCurrent
48590000
CY2022Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
4142000
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
2155000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3443000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4945000
CY2022Q2 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
120000
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
587000
CY2022Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
52624000
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
56277000
CY2021Q1 adgi Milestone Payment
MilestonePayment
1000000.0
CY2021Q2 adgi Milestone Payment
MilestonePayment
2500000
CY2021Q3 adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
39900000
adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
39900000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
40000000.0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
5000000
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
adgi Quarterly Fee
QuarterlyFee
1300000
CY2021Q2 adgi Quarterly Fee
QuarterlyFee
0
adgi Quarterly Fee
QuarterlyFee
0
adgi Delivery Fee
DeliveryFee
200000
adgi Completion Fee
CompletionFee
200000
adgi Exercise Fee
ExerciseFee
1000000.0
CY2022Q2 adgi Accrued Upfront Fee
AccruedUpfrontFee
200000
us-gaap Royalty Expense
RoyaltyExpense
0
adgi Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
200000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
161000
us-gaap Operating Lease Cost
OperatingLeaseCost
266000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
8000
us-gaap Variable Lease Cost
VariableLeaseCost
16000
CY2022Q2 us-gaap Lease Cost
LeaseCost
169000
us-gaap Lease Cost
LeaseCost
282000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
176000
us-gaap Operating Lease Payments
OperatingLeasePayments
276000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
553000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1113000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
713000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
430000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
328000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3137000
CY2022Q2 adgi Operating Lease Liability Adjustment
OperatingLeaseLiabilityAdjustment
279000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2858000
CY2022Q2 adgi Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.060
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2022Q2 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1000000.0
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1900000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
16944484
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18871592
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.15
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24897000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6574509
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
148353
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5361664
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.62
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19936084
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6972000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
19936084
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.73
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6972000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4272473
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2976000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.88
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3082175
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
450995
adgi Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Repurchased In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRepurchasedInPeriod
2150737
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
480443
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6361000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3342000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8344000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3929000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4600000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
86400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2021Q3 adgi Percentage Of Total Number Of Shares Of Common Stock Outstanding
PercentageOfTotalNumberOfSharesOfCommonStockOutstanding
0.01
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2685546
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-50990000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-44673000
us-gaap Net Income Loss
NetIncomeLoss
-151656000
us-gaap Net Income Loss
NetIncomeLoss
-83373000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108166890
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108166890
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
249769
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
249769
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108019051
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
108019051
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125574
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125574
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-178.86
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-178.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-663.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-663.94
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20416527
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20416527
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
103848980
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
103848980

Files In Submission

Name View Source Status
0000950170-22-017242-index-headers.html Edgar Link pending
0000950170-22-017242-index.html Edgar Link pending
0000950170-22-017242.txt Edgar Link pending
0000950170-22-017242-xbrl.zip Edgar Link pending
adgi-20220630.htm Edgar Link pending
adgi-20220630.xsd Edgar Link pending
adgi-ex31_1.htm Edgar Link pending
adgi-ex31_2.htm Edgar Link pending
adgi-ex32_1.htm Edgar Link pending
adgi-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
adgi-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
adgi-20220630_pre.xml Edgar Link unprocessable
adgi-20220630_def.xml Edgar Link unprocessable
adgi-20220630_lab.xml Edgar Link unprocessable
adgi-20220630_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending